Table 3 Percentage of time in therapeutic range (1.8–3.2) after stratification by valve position.
Aortic valve | Mitral valve | |||||
|---|---|---|---|---|---|---|
Genotype-based dosing group (n = 16) | Standard dosing group (n = 18) | P-value | Genotype-based dosing group (n = 20) | Standard dosing group (n = 23) | P-value | |
Traditional method (%) | ||||||
First 1 week | 58.5 ± 10.1 | 38.1 ± 26.8 | 0.009 | 44.6 ± 23.5 | 39.6 ± 21.9 | 0.477 |
Hospitalization | 55.8 ± 14.0 | 41.4 ± 24.5 | 0.042 | 41.1 ± 21.6 | 36.9 ± 21.9 | 0.527 |
Until first outpatient visit | 52.1 ± 15.2 | 39.2 ± 20.0 | 0.047 | 43.5 ± 19.8 | 37.1 ± 21.7 | 0.327 |
Rosendaal method (%) | ||||||
First 1 week | 64.0 ± 12.3 | 44.6 ± 27.3 | 0.012 | 53.4 ± 22.5 | 46.9 ± 23.2 | 0.369 |
Hospitalization | 60.5 ± 14.3 | 45.4 ± 25.7 | 0.041 | 47.9 ± 22.9 | 44.0 ± 23.4 | 0.581 |
Until first outpatient visit | 53.3 ± 22.8 | 46.2 ± 23.7 | 0.387 | 53.5 ± 25.4 | 48.2 ± 27.1 | 0.513 |
